Casanova Michela, Massimino Maura, Ferrari Andrea, Spreafico Filippo, Piva Luigi, Coppa Jorgelina, Luksch Roberto, Cefalo Graziella, Terenziani Monica, Polastri Daniela, Bellani Franca Fossati, Mazzaferro Vincenzo
Pediatric Oncology Unit, Istituto Nazionale Tumori, Via Venezian, 1-20133 Milano, Italy.
Pediatr Hematol Oncol. 2005 Apr-May;22(3):189-98. doi: 10.1080/08880010590921441.
To discuss the potential benefit of a chemotherapy regimen including etoposide (etoposide, cisplatin, epirubicin [EPE]), the authors report a single-institutional experience regarding 13 children with hepatoblastoma (HB) and 7 with hepatocellular carcinoma (HCC). Chemotherapy achieved partial response in 8/9 HB and in 4/5 HCC. Eight initially unresectable HB subsequently had liver resection. Event-free survival and overall survival at 5 years were 84 and 88% for HB (non-metastatic cases: 91 and 100%), 29% for HCC. EPE chemotherapy seems to be effective in the treatment of childhood malignant liver tumors. Etoposide could be suggested as part of intensive multidrug regimens for HCC and high-risk HB.
为探讨包含依托泊苷（依托泊苷、顺铂、表柔比星[EPE]）的化疗方案的潜在益处，作者报告了一项单机构经验，涉及13例肝母细胞瘤（HB）患儿和7例肝细胞癌（HCC）患儿。化疗使9例HB中的8例以及5例HCC中的4例获得部分缓解。8例最初无法切除的HB随后接受了肝切除术。HB的5年无事件生存率和总生存率分别为84%和88%（非转移性病例：91%和100%），HCC为29%。EPE化疗似乎对儿童恶性肝肿瘤的治疗有效。对于HCC和高危HB，可建议将依托泊苷作为强化多药方案的一部分。
